The goals of Type 2 diabetes treatment are to eliminate the hyperglycemia resulting from insulin insufficiency and/or insulin resistance, delay beta cell damage/depletion, and prevent other metabolic co-morbidities and complications. In the current treatment algorithms, lifestyle changes (medical nutrition therapy, physical exercise) and oral anti-diabetics are followed by insulin therapy, which is considered a replacement therapy for Type 2 diabetes. Pre-mixed insulin preparations, which are an option for patients with poor blood glucose level control under oral anti-diabetics treatment, have been developed to meet both basal and prandial insulin needs by simulating the physiological changes in insulin levels. The consensus on the necessit...
The effectiveness of BIAsp 30 step-up therapy in achieving glycemic control in Japanese patients wit...
Aim. To evaluate efficiency and safety of intensification of therapy by substituting two-phase ins...
AIMS: Despite a wealth of clinical trial data supporting use of the premixed insulin analogue, bipha...
The goals of Type 2 diabetes treatment are to eliminate the hyperglycemia resulting from insulin ins...
Recently, the prevalence of type 2 diabetes has reached pandemic levels all over the world, and the ...
Insulin degludec/insulin aspart (IDegAsp) is a fixed-ratio co-formulation of insulin degludec (IDeg)...
Given the progressive nature of type 2 diabetes (T2D), most individuals with the disease will ultima...
Type 2 diabetes (T2D) represents an escalating burden worldwide, particularly in China and India. Co...
peer reviewedType 2 diabetes is a heterogeneous disease resulting from a dynamic interaction between...
Introduction: To evaluate the clinical profile of BIAsp 30 (30 soluble insulin aspart, 70 protamine-...
60?70% of all patients with Type 2 Diabetes Mellitus will ultimately require insulin therapy for the...
Aim. To assess efficiency and safety of therapy at the onset and after intensification of the trea...
The efficacy benefits of biphasic insulin aspart formulation (BIAsp 30) in patients with diabetes me...
Background: It is estimated that 39% of people with diabetes worldwide who use insulin are prescribe...
Aim: To determine the safety and efficacy of biphasic insulin aspart 30 (BIAsp 30) therapy in the In...
The effectiveness of BIAsp 30 step-up therapy in achieving glycemic control in Japanese patients wit...
Aim. To evaluate efficiency and safety of intensification of therapy by substituting two-phase ins...
AIMS: Despite a wealth of clinical trial data supporting use of the premixed insulin analogue, bipha...
The goals of Type 2 diabetes treatment are to eliminate the hyperglycemia resulting from insulin ins...
Recently, the prevalence of type 2 diabetes has reached pandemic levels all over the world, and the ...
Insulin degludec/insulin aspart (IDegAsp) is a fixed-ratio co-formulation of insulin degludec (IDeg)...
Given the progressive nature of type 2 diabetes (T2D), most individuals with the disease will ultima...
Type 2 diabetes (T2D) represents an escalating burden worldwide, particularly in China and India. Co...
peer reviewedType 2 diabetes is a heterogeneous disease resulting from a dynamic interaction between...
Introduction: To evaluate the clinical profile of BIAsp 30 (30 soluble insulin aspart, 70 protamine-...
60?70% of all patients with Type 2 Diabetes Mellitus will ultimately require insulin therapy for the...
Aim. To assess efficiency and safety of therapy at the onset and after intensification of the trea...
The efficacy benefits of biphasic insulin aspart formulation (BIAsp 30) in patients with diabetes me...
Background: It is estimated that 39% of people with diabetes worldwide who use insulin are prescribe...
Aim: To determine the safety and efficacy of biphasic insulin aspart 30 (BIAsp 30) therapy in the In...
The effectiveness of BIAsp 30 step-up therapy in achieving glycemic control in Japanese patients wit...
Aim. To evaluate efficiency and safety of intensification of therapy by substituting two-phase ins...
AIMS: Despite a wealth of clinical trial data supporting use of the premixed insulin analogue, bipha...